|

Assessment of Geriatric Evaluations Impact on New AML Guidance

RECRUITINGSponsored by Abramson Cancer Center at Penn Medicine
Actively Recruiting
SponsorAbramson Cancer Center at Penn Medicine
Started2023-10-25
Est. completion2026-12-01
Eligibility
Age50 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05909501

Summary

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

* AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
* New diagnosis being considered for new line of treatment
* Age ≥ 50 years.
* Performance status 0,1, and 2

Exclusion Criteria:

* Inability to understand or unable to sign a written informed consent
* Unable to fill out questionnaires on their own and/or do not have someone to help complete them

Conditions2

AML, AdultCancer

Locations1 site

Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, 19104

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.